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Prevention of Bladder  
Tumor Recurrence 
Shapiro Amos and Ofer N. Gofrit 
The Department of Urology, Hadassah University Hospital, Jerusalem, 
Israel  
The Way to Prevent Tumor Impantation is by Washing out the Cancer Cells and Prevent Its 
Addherence Prevention of Tumor Recurrence After Transurethral Resection by Means of 
Bladder Irrigation with Distilled Water - A Prospective Randomized Study with a Long-
Term Follow-up. 
1. Introduction 
Superficial papillary tumors of the bladder recur in about 70% of patients in the first 2 years 
following treatment by transe urethral resection (TUR). Since there is no other evidence of 
mucosal changes in random biopsies it seems that the high recurrence rate is due to tumor 
implantation. We tried to find out whether irrigation with distilled water of the bladder 
following TUR will reduce tumor recurrence.  
2. Material and methods 
Sixty nine patients were enlisted for a prospective randomized controlled study in order to 
investigate the efficacy of bladder irrigation with distilled water for 24 hours following a 
transurethral resection of first time papillary transitional cell tumors of the urinary bladder. 
These patients were compared to a group of patients that were not irrigated at all. There 
were 31 patients in the first group and 38 in the control. All patients had grade 2 transitional 
cell tumors (average 1.2 tumors per patient). Random biopsies that were taken at the time of 
operation showed no additional pathology.  
3. Results 
In the irrigated group there were 8 (25%) recurrences in the first 24 months of follow-up 
while at the same period of time there were 22 (58%) recurrences in the control group, 
p=0.007 (using a chi square analysis). On longer follow-up of between 2 to 10 years (mean 6 
years) there was no difference in tumor appearance between the two groups 8 out of 23 
(37%) in the irrigated group and 5 out of 16 (31%) in the remaining patients in the control 
group, p=0.6119 using the same statistical tool. The recurrence rate of low-grade superficial 
papillary tumor of the bladder is about 70% (1). Most of the recurrences occur in the first 
year after the tran-urethral tumor resection (TUR) and 95% of the recurrence occur within 
two years after the resection (2). Although this is a low grade malignant tumor and biopsies 
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that are taken randomly at the time of the resection are normal, the tumor shows a high 
tendency to recur, and this observation needs some sort of biological explanation. The 
tumors tend to occur at the bladder neck where the resectoscope most frequently injures the 
normal mucosa and at the dome of the bladder where distention of the bladder while 
inflating it during the operation tends to crack the epithelial lining. During transurethral- 
resection of a bladder tumor many viable malignant cells are floating free in the bladder and 
have the capability of adhering to a raw surface in the bladder (3). These two facts lead to 
the idea that the recurrence is iatrogenic: meaning that cells that were floating in the bladder 
during the TUR are implanted into the injured bladder mucosa. If this hypothesis is correct 
then elimination of the viable cells and disabling of the adhesive properties of the cells 
should significantly lower the recurrence rate of this tumor. Distilled water irrigation of the 
bladder should reach these goals. In order to prove this hypothesis a controlled randomized 
study was conducted from 1983 until 1990 in which the efficacy of washing the bladder with 
12 liters of water in 24h was compared to no irrigation during the post operative period. 
Tumor occurrences were compared in these two groups at the end of the first two years and 
from then on.  
4. Patients selection 
Eighty four patients entered the study, 15 had high grade tumors or carcinoma in situ and 
the were treated right away with Bacille Calmette Guerin (BCG), therefore the effect of 
irrigation could not be monitored in them. The remaining sixty-nine patients with first time 
low-grade superficial transitional cell tumors were studied for the effect of irrigation on 
tumor recurrence. There were fifty-three males and sixteen females. They were between the 
ages of 40-90 years old with a mean age of 62. They did not have any other known 
malignancy and were not treated for any previous diseases in the bladder. The diagnosis of 
the tumor was made at the outpatient clinic and all patients underwent a standard TUR 
with random bladder biopsies in order to exclude carcinoma in situ. In all cases previous to 
the operation urine cytology was sent and IVP was performed and was normal in all studied 
patients. Randomization was done after the completion of the surgical intervention by 
blindly selecting a note from an envelope which stated whether or not the patient should be 
irrigated. In the group randomized for irrigation, the irrigation was through a regular a 20F 
Folly catheter. In the group randomized for irrigation, instructions were given to irrigate the 
bladder at a rate two liters of distilled water every 4h for 24h.  
5. Results  
There were 69 patients in this study. Thirty-one were irrigated and 38 were not. The recurrence 
rate of the irrigated group within 24 months after the TUR was 8 patients 25%. while the 
recurrence rate of the non-irrigated patients during the same period of time was 22 patients 
58%. The statistical difference between these two groups is p, = 0.0079 using a Chi square test 
.(The recurrence rate of the irrigated patients between 2-10 years with a mean follow-up of 6 
years was 7 patients out of the 23 remaining patients 34%. While the recurrence rate of the 
non-irrigated patients at the same period of time with the same mean follow-up was 5 out of 
the 16 remaining patients 32%. There was no statistical significance difference between these 
two groups at this period of time. P=0.6119 using the same statistical analysis. The number of 
the primary tumors (1.2)was the same in both groups; so were the size of the tumors (1.7cm) 
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and the mean age of the treated patients appearance of tumor which most probably occurs due 
to the continued insult by carcinogens to the bladder mucosa.  
6. Conclusions 
Water irrigation of the bladder following a TUR is very effective in preventing early 
recurrence of low grade papillary transitional cell tumors. It achieves this goal by 
mechanical expulsion of floating tumor cells and by preventing the cells from adhere. 
Detection of tumors by Raman spectrum 
There is a need to detect bladder cancer as early as possible in order to improve cure rateIn 
order to detect bladder cancer as early as possible to allow effective BCG treatment/ We 
conducted an experiment using a green laser to find the Raman signal os bladder cancer cells 
voided in the urine/ The use of Raman Spectroscopy in the diagnosis of bladder cancer from 
cells voided in the urine Urine cytology is expensive and inaccurate in detecting bladder 
tumors. The late diagnosis of invasive bladder cancer is a major medical and economical 
problem because bladder cancer is the fifth most frequent cancer in the western world. Today 
85% of patients with high grade tumors, have invasive cancer at diagnosis. To address this 
problem we use Raman Molecular Imaging (RMI) to improve the accuracy of urine cytology. 
RMI is an innovative technology that combines the molecular chemical analysis capacity of 
Raman Spectroscopy with high definition digital image microscopic visualization. Digital 
imaging information and Raman Spectra show unique "Finger Print" Spectra of the different 
cells voided in the urine. The goal of this project is show that this method is accurate in the 
diagnosis of bladder cancer. Methods: Bladder cancer tissue with known diagnosis(10 Ta.G1) 
(10 T2-3. G3)and 2 normal bladders were scanned using a FALCON Raman imaging 
microscope. The typical Spectral Finger print of cells from samples of each pathology was 
characterized. Tissue samples were compared to voided cells in the urine and the same spectra 
were obtained from the same pathology. Further measurements on 45,49 and 50 urine samples 
from G3,G1 and G0 cases. Results: Using tissue, the G3 tumors gave a very high pick of scatter 
at 1584 cm-1 Raman shift. G1 tumors showed a less prominant but a significant elevation at 
this shift. While G0 did not show this elivation. Raman imaging showed that the material 
responsible for the signal was confined to the cells.  
Fourty nine patients with no tumor showed 0% false positive results. In 45 patients with G3 
tumors 44. (98%) showed the signal of a tumor and 41 (94%) showed that the tumor is of 
high grade. In 50 G1 tumors all were detected as tumor and there were only 2 samples that 
gave the high grade signal. In the RMI there is a distinctive difference between high grade 
and low grade tumors and non malignant cells. Conclusions: With this more reliable test it 
will be easier to find this tumor at its initial state. RMI shows that the signal from bladder 
cancer tissue and cells voided in the urine can be identified and distinguished from normal 
bladder tissue and cells in a very high accuracy rate and should be used in screening the 
high risk population. 
This study was published in the January 2011 in Europian Uroiogy. This examination can be 
performed with the aid of a computer and does not require a pathologist or a Urologist. This 
presentation details the use of a software algorithm and Raman Spectroscopy to rapidly 
identify malignancy from cells in voided urine. The spectrum is analyzed by a software 
algorithm which removes interpreter bias from the analysis.  
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7. Methods 
Cellular analysis was performed on urine collected from patients with and without TCC of the 
bladder. The urine was spun. The supernatant was discarded and the palette was suspended 
with distilled water. The process was repeated. The remaining material was placed into a 
Cytospin chamber which resulted in cells being deposited on an aluminum slide. Each slide 
was analyzed with the Falcon Microscope. The epithelial cells were photographed using 50x 
objective magnification. Raman spectra were obtained using 100 objective so as to minimize 
the empty space around the cell. At first spectra were obtained from 172 slides with an average 
of 5 cells per slide. The results led to formulation of the algorithm. Than the algorithm was 
tested on 196 additional cases. Results. The initial 172 samples were as follows: GO-50, G1-50, 
G3-50, CIS-22. Accuracy was as follows: G0-90%, G1-88%, G3-100%, CIS-95.5%. This analysis 
served to produce a software algorithm to identify characteristic signals produced by RMI. The 
algorithm was applied to another 196 samples made up of GO-76, G1-52, and G3-68 were 
analyzed. The algorithm's accuracy was: G0-90%, G1 57%, G3-97%. Conclusions. RMI of cells 
in voided urine can accurately distinguish benign from malignant pathology. Application of a 
software algorithm to the cellular spectrum rapidly and independent of operator bias 
segregregates benign from malignant cells.  
Comparison of BCG types 
Since BCG is the most effective treatment in preventing tumor recurrence we conducted a 
study to find out whether live bacteria or froze dried one is more effective Comparison of 
the efficacy and side effects of Pasteur vs. Connaught Bacille Calmette Guerin (BCG) 
treatment of Superficial bladder tumors One of the unclear area in treating superficial 
bladder tumors with Bacille Calmette Gguerin (BCG) is which preparation is the  
most effective one, and what are the relations between successful treatment and the side 
effects of it.  
8. Material and methods 
In order to find out which preparation of BCG 1) a freeze dried or 2) a fresh living 
suspension, are most effective and has a lower side effect Material and Methods: A 
controlled randomized study was done comparing the Connaught Imucyt to the original 
Pasteur strain. There were 66 patients in the study, 34 were in Pasteur strain and 32 in the 
Connaught strain. Each treatment consisted of 6 weekly installations of either 175 mg of 
Pasteur BCG or 108 mg of Imucyt. There were 50 males and 16 females. The mean age was 
64 (39-86). Forty five patients had a papillary tumors, 22 grade 2, 20 grade 3, and 3 grade 4. 
Four patients had a stage A tumor and the rest had stage O tumors. Twenty two patients 
had Carcinoma In Situ. Results: In a mean follow-up period of 61.5 months the recurrence 
rate of The Connaught strain was 11 (34%) and in the Pasteur strain 10 (29%) there is no 
statistical difference between the preparations. The same amount of side effects occurred in 
both treatments. Not even one patient had to withdraw from the treatment.  
9. Conclusions 
Both Connaught and Pasteur BCG preparations are equally effective with the same amount 
of side effects. Sixty six patients with recurrent papillary transitional tumor or patients with 
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biopsy proven carcinoma in situ (CIS) of the bladder were randomly treated with BCG 
following a TUR or biopsies for CIS. Thirty four were treated by a six weekly Pasteur fresh 
BCG (150 mg./ treatment) and 32 were treated with Connaught frozen-dried BCG (108 
mg./treatment). Their mean age was 64 (39-86), 50 were men and 16 women. The tumor 
grades were: 22 grade 2, 20 grade 3, and 3 grade 4. Four patients had Ta tumors the rest had 
T1 tumors according to the ICCU calcification of bladder cancer. Twenty two patients had 
CIS. The age, grade, stage, sex were equally devided between the two groups. The mean 
follow-up time was 61.5 months (55-67) In order to find out which preparation of BCG 1) a 
freeze dried or 2) a fresh living suspension, are most effective and has a lower side effect.  
10. Material and methods 
A controlled randomized study was done comparing the Connaught Imucyt to the original 
Pasteur strain. There were 66 patients in the study, 34 were in Pasteur strain and 32 in the 
Connaught strain. Each treatment consisted of 6 weekly installations of either 175 mg of 
Pasteur BCG or 108 mg of Imucyt. There were 50 males and 16 females. The mean age was 
64 (39-86). Forty five patients had a papillary tumors, 22 grade 2, 20 grade 3, and 3 grade 4. 
Four patients had a stage A tumor and the rest had stage O tumors. Twenty two patients 
had Carcinoma In Situ.  
11. Results 
In a mean follow-up period of 61.5 months the recurrence rate of The Connaught strain was 
11 (34%) and in the Pasteur strain 10 (29%) there is no statistical difference between the 
preparations. The same amount of side effects occurred in both treatments. Not even one 
patient had to withdraw from the treatment.  
12. Conclusions 
Both Connaught and Pasteur BCG preparations are equally effective with the same amount 
of side effects.  
13. Conclusions  
It seems from our study that there is not any difference between the two preparations of 
Pasteur and Connaught BCG, not in the response to treatment, and not in the side effects. 
Therefore it is recommended to use any one of these preparations according to the 
convenience of the treating physician.  
Lamm, DL., van der Meijden, PM., Morales, A., Brosman, S., Catalona, WJ., Herr HW., 
Solloway, MS., Steg,A. and Debruyne, FM.: Incidence and treatment of complications of 
bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147: 596-
600. 1992.  
Treatment of T1 Tumors 
In high grade superficial tumors the recurrence of non BCG treated patients is about 90% in 
2 years. With BCG treatment our results are: 40 patients with T1 intermediate (G2) and high 
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grade (G3) bladder cancer were treated in Hadassah university hospital from 1983 to 2001. 
All the patients were treated by transe-urethral removal (TUR) of the tumor and additional 
Bacille Calmette Guerin (BCG) immunotherapy to the affected bladder. The mean follow-up 
to failure, death or to last examination was 120 months (12-228) . There were 32 patients that 
had no evidence of disease in this period of time. One patient was lost for follow-up 6 
months after the diagnosis of his disease. 5 patients had invasive tumor recurrence and 
needed cystectomy 2 had recurrent low grade superficial tumors and were treated by a 
TUR. Four patients had metastatic disease on recurrence they all died within 2 years after 
the methastasis was discovered. They were treated by MVAC chemotherapy (3) or no 
treatment at all (1).  
mRNA of IL2 and response to BCG treatment 
We showed in the June 1996 issue of JCO that IL-2 is needed for the activity of BCG Novel 
Approach to Treatment of Bladder Cancer by Analysis of Interleukin-2 Gene Activation 
Carcinoma in situ is treated solely with BCG. However, 1/3 of these patients will fail 
treatment and suffer relapse. In lymphoid cells isolated from bladder cancer patients during 
BCG treatment, we studied the expression of two genes essential for regulation of an 
adequate immune response, encoding interleukin-2 (IL-2) and interferon-gamma. IL-2 and 
IFN-gamma are Th1 cytokines with many critical functions; they are essential for protective 
immunity and major players in the anti-tumor response. To this end, we developed a 
method that accurately measures the induced expression of IL-2 and IFN-gamma mRNA in 
peripheral blood mononuclear cells (PBMC) from only 10 ml of peripheral blood. Our 
finding is that the ability of the IL-2 gene to be activated is a highly accurate predictive 
parameter of cure from bladder cancer: 97% of patients whose IL-2 gene is inducible will 
enter remission. By contrast, up to 90% of patients whose IL-2 gene failed to respond to a 
stimulus had relapse or persistence of the tumor (Kaempfer et al., J Clin Oncol 14:1778-1786, 
1996). Our findings strongly suggest that expression of the patient's own IL-2 gene is 
essential for mounting an anti-tumor response. This is the first instance of successful 
prediction of clinical outcome during cancer treatment, well before any symptoms of 
relapse. Determination of induction of IL-2 mRNA in a patient's PBMC provides feedback 
on the response of the patient even before termination of treatment. Patients showing a lack 
of inducibility of IL-2 mRNA thus can receive alternative treatment well before tumors 
recur. We propose to apply insight gained from analysis of IL-2 gene activation towards 
rescuing the 1/3 of bladder cancer patients that will fail standard treatment with BCG. Our 
strategy will be first to identify such patients by the inability of their IL-2 gene to respond to 
induction during treatment with BCG, and then to subject this subset to a second course of 
BCG treatment, either alone or in combination with human rIL-2. This combination of BCG 
and IL-2 was proven safe in a recent phase I study we performed and in a phase II study 
was more effective than conventional BCG treatment. Such an approach, we postulate, may 
elicit in these patients the needed anti-tumor response - at an early stage and well before 
relapse occurs - and lead to cure. We believe that our previous research creates an unusually 
strong basis for this project, which involves a close collaboration between a molecular 
biologist (RK) and a uro-oncologist (AS) at Hadassah Medical Center. From a scientific point 
of view, it will allow rigorous testing of the role of endogenous IL-2 gene activation in the  
anti-tumor response.  
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External IL2 and BCG treatment 
As aresult of this study we tested the possibility of adding external IL-2 to the BCG 
treatment Phases I and II in the IL-2 BCG intravesical treatment of bladder tumors The 
standard treatment of superficial recurrent bladder tumor is intravesical instillation of BCG. 
The expression of il-2 is necessary for the success of the BCG immunotherapy. (Kaempfer & 
Shapiro JCO June 1966). 
The treatment of bladder cancer with a combination of BCG and IL2 
Using IL-2 along with an intravesical instillation of BCG has been shown to be successful 
when treating superficial bladder cancer along with BCG. We propose to find out whether 
the addition of IL-2 to BCG treatments will convert patients that would fail the traditional 
BCG treatment to responders of the combined treatment. A phase I study was undertaken to 
asses the toxicity of the Intravesical application of IL-2 to the bladder in concentrations 
ranging from 6 million units to 54 million units per treatment in conjunction with standard 
BCG (Tice or Connaught). Due to the considerable time involved with patient recruitment, 
phase II studies were done in conjunction with the phase I work. All 19 patients completed 
the Phase I study and all patients participated during the follow-up period. In the Phase I 
study, there were 20 repots of a fever higher than 38 degrees centigrade that lasted from 1-3 
days in 10 patients. They did not need any medications for this side effect and it did not 
prevent them from completing the study (table 1). One Patient had severe arthralgia and 
fever 3 weeks after the last (6th) treatment and was treated with dual anti-tuberculosis 
medication and later by 3 Hydrocortisone injections. The response to the treatment was a 
complete recovery from the arthralgia. The blood tests for urea, electrolytes, liver and 
thyroid were all in the normal range during the treatment and follow-up periods. The 
cytology test for Bladder cancer was negative before, during and after treatment. 
Cystoscopy performed after the initial treatment at months: 3, 6, 9, 12, 16, 20, 24 and 30 were 
all free of tumors except for 3 patients. The recurrence happened in 1-3 years and all the 
patients did not quit smoking. The bladder was a bit red as observed following BCG 
treatment. 18  
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